Psyence Group Inc
Psyence Group Inc., a life science biotechnology company, engages in the research, cultivation, and production of psychedelics and nature-based compounds to treat psychological trauma. It operates in two segments, Clinical Trial Activities and Non-Clinical Trial Activities. The company develops botanical psilocybin-based psychedelic medicine, which works with natural psilocybin products for the h… Read more
Psyence Group Inc (PSYGF) - Total Assets
Latest total assets as of September 2025: $895.96K USD
Based on the latest financial reports, Psyence Group Inc (PSYGF) holds total assets worth $895.96K USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Psyence Group Inc - Total Assets Trend (2016–2025)
This chart illustrates how Psyence Group Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Psyence Group Inc - Asset Composition Analysis
Current Asset Composition (March 2025)
Psyence Group Inc's total assets of $895.96K consist of 89.6% current assets and 10.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 83.8% |
| Accounts Receivable | $200.73K | 1.9% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $14.90K | 0.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Psyence Group Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Psyence Group Inc's current assets represent 89.6% of total assets in 2025, a decrease from 100.0% in 2016.
- Cash Position: Cash and equivalents constituted 83.8% of total assets in 2025, down from 100.0% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 1.9% of total assets.
Psyence Group Inc Competitors by Total Assets
Key competitors of Psyence Group Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Novartis AG
PINK:NVSEF
|
USA | $115.49 Billion |
|
Pfizer Inc
NYSE:PFE
|
USA | $208.73 Billion |
|
AbbVie Inc
NYSE:ABBV
|
USA | $133.96 Billion |
|
Biogen Inc
NASDAQ:BIIB
|
USA | $29.44 Billion |
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
|
Zhejiang Zhenyuan Share Co Ltd
SHE:000705
|
China | CN¥3.03 Billion |
|
Hunan Jingfeng Pharmaceutical
SHE:000908
|
China | CN¥877.99 Million |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
|
China | CN¥2.58 Billion |
Psyence Group Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Psyence Group Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Psyence Group Inc is currently not profitable relative to its asset base.
Psyence Group Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 16.88 | 0.94 | 0.91 |
| Quick Ratio | 16.88 | 0.94 | 0.91 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $830.03K | $ -216.65K | $ -12.26K |
Psyence Group Inc - Advanced Valuation Insights
This section examines the relationship between Psyence Group Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.08 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 224.1% |
| Total Assets | $10.60 Million |
| Market Capitalization | $70.01K USD |
Valuation Analysis
Below Book Valuation: The market values Psyence Group Inc's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Psyence Group Inc's assets grew by 224.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Psyence Group Inc (2016–2025)
The table below shows the annual total assets of Psyence Group Inc from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | $10.60 Million | +224.06% |
| 2024-03-31 | $3.27 Million | -18.22% |
| 2023-03-31 | $4.00 Million | -8.11% |
| 2022-03-31 | $4.35 Million | +3397.44% |
| 2021-03-31 | $124.51K | -11.53% |
| 2020-03-31 | $140.74K | -18.75% |
| 2019-03-31 | $173.22K | +24126.57% |
| 2018-03-31 | $715.00 | -10.06% |
| 2017-03-31 | $795.00 | 0.00% |
| 2016-03-31 | $795.00 | -- |